Glofitamab联合Pola-R-CHP治疗初诊弥漫大B细胞淋巴瘤的多中心II期研究
该多中心II期试验评估CD3xCD20双特异性抗体Glofitamab联合Pola-R-CHP方案治疗IPI≥2分的初诊弥漫大B细胞淋巴瘤患者,共入组41例。最佳完全缓解率达95%(95%CI 83-99),中位随访23.9个月,24个月无进展生存率为95%(95%CI 89-100)。细胞因子释放综合征发生率低(10%,均为1级),未报告免疫效应细胞相关神经毒性综合征。
要点
- Glofitamab延迟加入Pola-R-CHP方案,最佳完全缓解率达95%。
- 中位随访23.9个月,24个月无进展生存率为95%。
- 细胞因子释放综合征发生率10%(均为1级),无免疫效应细胞相关神经毒性综合征。
核心结论
- Glofitamab联合Pola-R-CHP在初诊高危弥漫大B细胞淋巴瘤中产生高完全缓解率和持久缓解的初步证据,且安全性可控。
研究设计与样本
- 多中心II期试验,入组41例初诊弥漫大B细胞淋巴瘤且国际预后指数≥2分的患者。
- 患者先接受2周期Pola-R-CHP(允许1周期R-CHOP),第3至6周期加入Glofitamab,第7至8周期Glofitamab单药治疗。
- 主要终点为最佳完全缓解率。
主要发现
- 最佳完全缓解率为95%(39/41)(95%CI 83-99),治疗结束时2例部分缓解患者未经干预转为完全缓解。
- 中位随访23.9个月,中位无进展生存期未达到,24个月无进展生存率为95%(95%CI 89-100)。
- 4例(10%)发生细胞因子释放综合征,均为1级;未报告免疫效应细胞相关神经毒性综合征。
关键数值与推荐
- 最佳完全缓解率95%(39/41)(95%CI 83-99)。
- 24个月无进展生存率95%(95%CI 89-100)。
- 细胞因子释放综合征发生率10%(4/41),均为1级;免疫效应细胞相关神经毒性综合征0例。
临床怎么用
- 该方案采用延迟加入Glofitamab的策略,细胞因子释放综合征发生率低且无神经毒性,支持进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this phase II trial, we evaluated the addition of the CD3xCD20 bispecific antibody, glofitamab (glofit) to polatuzumab, rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) and an international prognostic index (IPI) ³ 2. Patients received two cycles of pola-R-CHP (one cycle of R-CHOP allowed). Glofitamab was added to pola-R-CHP during cycles 3 through 6 and used as monotherapy for cycles 7 and 8. The primary objective was the best complete response (CR) rate. A total of 41 patients enrolled. The median age was 61 years (range 35-86), and 59% were male. IPI scores were 2 (39%), 3 (41%), and 4 (20%), and 86% of patients had stage III/IV disease. Most patients had DLBCL, NOS (78%) and 12% had high grade B-cell lymphoma with translocations in MYC and BCL-2 and/or BCL-6. The best CR rate was 95% (39/41) (95% CI: 83-99) and both patients with a partial response at the end of therapy converted to CR without intervention. With a median follow-up of 23.9 months, the median progression-free survival (PFS) has not been reached and the 24-month PFS was 95% (95% CI: 89-100). Four (10%) patients developed cytokine release syndrome (CRS) (all grade 1), and no immune effector cell-associated neurotoxicity syndrome (ICANS) was reported. Glofit-pola-R-CHP resulted in high rates of CR and preliminary evidence of durable responses and the schedule, with delayed incorporation of glofit, resulted in low rates of CRS and no neurotoxicity. These data support further evaluation of this regimen. NCT05800366.
引用
- Crombie JL, Redd R, Phinney C, et al. A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with diffuse large B-cell lymphoma. Blood. 2026. PMID: 42837325. doi:10.1182/blood.2026034588
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。